BioSpace News Archive

Reneo Pharmaceuticals, Inc. today announced that the company has achieved the target enrollment in the pivotal STRIDE study of mavodelpar (REN001) in primary mitochondrial myopathies (PMM).

BlueRock Therapeutics LP today announced a collaboration with Rune Labs and Emerald Innovations focused on using wearable and invisible contactless digital health technology to improve monitoring and data collection for Parkinson’s disease clinical trials.

Enveric Biosciences announced today new research detailing the first-ever isolation of a novel indolethylamine N -methyltran from cane toad (Rhinella marina) and the successful development of a bioproduction platform for the isolation and pharmacological screening of novel indolethylamines.

Bormioli Pharma today announced robust growth in its North American business in 2022, with sales increasing more than 40% year-over-year.

Ludwig Enterprises, Inc. and its subsidiary Precision Genomics has attracted significant clinical interest in its patent pending mRNA Inflammatory Index which measures inflammatory biomarkers that are associated with chronic diseases such as cancer, diabetes and heart disease.

MedAvail Holdings, Inc. (Nasdaq: MDVL) (“MedAvail”), an innovative pharmacy technology company, today announced that on March 13, 2023, it closed a private placement (the “Offering”) of securities with certain institutional investors pursuant to the terms of a definitive securities purchase agreement dated March 9, 2023.

Greater China region, Israel, and Greece, Cyprus and Malta are now also covered by the alliance. With the addition of three new WODA members - RareStone Group, CTS, and Path Pharma - WODA now provides access to 85 million rare disease patients.

ProQR Therapeutics N.V. (Nasdaq: PRQR) (ProQR), a company dedicated to changing lives through transformative RNA therapies, today announced it has successfully defended against two oppositions that were filed against a key patent for its ADAR-mediated RNA editing platform Axiomer®.

BioVie Inc. today announced registration details for BioVie Day— a virtual webinar to be held March 23, 2023 at 10 a.m. Eastern Standard Time.

Gradalis, Inc. today announced that data from a pilot study evaluating Vigil in combination therapy for the management of recurrent Ewing’s Sarcoma was published online in Clinical Cancer Research.